200 related articles for article (PubMed ID: 27573428)
1. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
Huibregtse KE; Vo KT; DuBois SG; Fetzko S; Neuhaus J; Batra V; Maris JM; Weiss B; Marachelian A; Yanik GA; Matthay KK
Eur J Cancer; 2016 Oct; 66():144-52. PubMed ID: 27573428
[TBL] [Abstract][Full Text] [Related]
2. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
Garaventa A; Gambini C; Villavecchia G; Di Cataldo A; Bertolazzi L; Pizzitola MR; De Bernardi B; Haupt R
Cancer; 2003 Mar; 97(5):1332-8. PubMed ID: 12599242
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
5. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
6. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
7. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
[TBL] [Abstract][Full Text] [Related]
8. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
[TBL] [Abstract][Full Text] [Related]
10. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.
Weiss B; Vora A; Huberty J; Hawkins RA; Matthay KK
J Pediatr Hematol Oncol; 2003 Jul; 25(7):543-7. PubMed ID: 12847321
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
12. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
Matthay KK; Quach A; Huberty J; Franc BL; Hawkins RA; Jackson H; Groshen S; Shusterman S; Yanik G; Veatch J; Brophy P; Villablanca JG; Maris JM
J Clin Oncol; 2009 Mar; 27(7):1020-5. PubMed ID: 19171714
[TBL] [Abstract][Full Text] [Related]
15. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.
Polishchuk AL; Dubois SG; Haas-Kogan D; Hawkins R; Matthay KK
Cancer; 2011 Sep; 117(18):4286-93. PubMed ID: 21387264
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.
Applebaum MA; Vaksman Z; Lee SM; Hungate EA; Henderson TO; London WB; Pinto N; Volchenboum SL; Park JR; Naranjo A; Hero B; Pearson AD; Stranger BE; Cohn SL; Diskin SJ
Eur J Cancer; 2017 Feb; 72():177-185. PubMed ID: 28033528
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
Anongpornjossakul Y; Sriwatcharin W; Thamnirat K; Chamroonrat W; Kositwattanarerk A; Utamakul C; Sritara C; Chokesuwattanasakul P; Thokanit NS; Pakakasama S; Anurathapan U; Pongphitcha P; Chotipanich C; Hongeng S
Nucl Med Commun; 2020 Apr; 41(4):336-343. PubMed ID: 31939898
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
19. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
[TBL] [Abstract][Full Text] [Related]
20. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
